G protein‐coupled receptor 30 contributes to improved remyelination after cuprizone‐induced demyelination. Issue 3 (22nd December 2012)

• Record Type: Journal Article
• Authors: Hirahara, Yukie; Matsuda, Ken Ichi; Yamada, Hisao; Saitou, Akira; Morisaki, Shinsuke; Takanami, Keiko; Boggs, Joan M.; Kawata, Mitsuhiro
• Is Part Of: Glia. Volume 61:Issue 3(2013:Mar.)
• Page Start: 420
• Page End: 431
• Publication Date: 2012-12-22
• Subjects: Neuroglia -- Periodicals; Neurology -- Periodicals; 611.0188
• DOI: 10.1002/glia.22445
• Languages: English
• ISSNs: 0894-1491

Abstract

<abstract abstract-type="main" xml:lang="en"> <title>Abstract</title> <p>Estrogen exerts neuroprotective and promyelinating actions. The therapeutic effect has been shown in animal models of multiple sclerosis, in which the myelin sheath is specifically destroyed in the central nervous system. However, it remains unproven whether estrogen is directly involved in remyelination via the myelin producing cells, oligodendrocytes, or which estrogen receptors are involved. In this study, we found that the membrane‐associated estrogen receptor, the G protein‐coupled receptor 30 (GPR30), also known as GPER, was expressed in oligodendrocytes in rat spinal cord and corpus callosum. Moreover, GPR30 was expressed throughout oligodendrocyte differentiation and promyelinating stages in primary oligodendrocyte cultures derived from rat spinal cords and brains. To evaluate the role of signaling via GPR30 in promyelination, a specific agonist for GPR30, G1, was administered to a rat model of demyelination induced by cuprizone treatment. Histological examination of the corpus callosum with oligodendrocyte differentiation stage‐specific markers showed that G1 enhanced oligodendrocyte maturation in corpus callosum of cuprizone‐treated animals. It also enhanced oligodendrocyte ensheathment of dorsal root ganglion (DRG) neurons in co‐culture and myelination in cuprizone‐treated animals. This study is the first evidence that GPR30 signaling promotes remyelination by oligodendrocytes after demyelination. GPR30 ligands may provide a novel therapy for the treatment of multiple sclerosis. © 2012 Wiley Periodicals, Inc.</p> </abstract>